Background:To investigate the contribution of right ventricular (RV) pacing sites to the cardiac function, this study compares plasma B-type natriuretic peptide (BNP) levels during RV septal and apical pacing in patients implanted with a pacemaker.Materials and Methods and Results:Seventy-four consecutive patients with indication for permanent pacing were included. To provide for the possibility of appropriate subgroup analyses, patients were stratified according to their pacing mode into two groups: Those with dual chamber DDD(R)/VDD pacemakers (41 patients, mean age 54.1±18.4 years), and those with single chamber VVI pacemakers (33 patients, mean age 60.6±18.4 years). A prospective single-blinded randomized design was used. Randomization (1:1 way) was between lead placement on the RV septum or RV apex and occurred during the implant in both groups. Compared to baseline, a significant decrease in BNP (429.8±103 pg/ml and 291.7±138 pg/ml, respectively) levels was observed during DDD(R) /VDD pacing after two months. In contrast, during VVI (R) pacing, a significant increase in BNP levels was observed (657.5±104 pg/ml and 889.5±139 pg/ml, respectively). To determine the impact of pacing sites on cardiac function, we assessed the changes in BNP levels in each group separately. Despite the significant difference in the pattern of changes between the two groups (P < 0.02), no significant changes were observed within groups regarding the acute effect of the pacing site (RV apex vs. RV septal) on BNP levels (P=NS).Conclusions:Our main result showed no significant differences between pacing sites and concluded that hemodynamic improvement could be substantially influenced by pacing mode, more than by pacing site.
As has been proven, increase of mechanical strain could result in an increase of brain natriuretic peptide (BNP) in the blood stream of implanted patient pacemakers. We measured the BNP concentration in blood due to different mode and lead implantation location of pacemaker in the time period of 3 months. The aim of this study was to investigate the changing trend of BNP level after pacemaker implantation. One hundred and three pacemaker implanted patients were monitored. Patients were in the age span of 54±12 years, including 48 men and 55 women. A group of 44 were programmed in Dual Chamber Rate Adaptive (DDDR) Pacemaker mode and a group of 59 were programmed in Ventricular Rate Modulated Pacing (VVIR) mode by the recommendation of the cardiologist. Between these two groups, the pacing levels of pacemakers was divided to under and above 50%. Some of these pacemaker leads were located at the apex of the right ventricle and the others were located in the septum wall in the right ventricle. To evaluate BNP changes during a period of 3 months, the BNPs were measured in pg/ml within 24 h of implantation (BNP1) and after 3 months (BNP2). For different classes of pacemaker implantations, the ratio of final measurement (BNP2) is divided to after implantation measurements (BNP1). Results showed that in VVIR mode, the ratio is 1.54±0.3 and in DDDR mode, the ratio is 0.38±0.17, with acceptable standard error means (<0.04). Also, comparisons are made for lead location at two modes of DDDR and VVIR separately. In the DDDR mode, the ratio for apex location is 0.49±0.12 and for septum location is 0.22±0.34, with acceptable standard error means (<0.02). In the VVIR mode, the ratio for apex location is 1.71±0.27 and for septum location is 1.28±0.09, with acceptable standard error means (<0.04). Therefore, BNP decrease in DDDR mode is more than in VVIR mode programming. In both cases of DDDR and VVIR modes, the septum location of the leads would result in a greater decrease of BNP.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.